Recent

% | $
Quotes you view appear here for quick access.

Aeterna Zentaris Inc. Message Board

pfw2141 65 posts  |  Last Activity: Jul 2, 2015 3:04 PM Member since: Apr 9, 2005
  • Reply to

    What A MannKind Investor Needs To Know

    by pfw2141 Jul 2, 2015 11:24 AM
    pfw2141 pfw2141 Jul 2, 2015 3:04 PM Flag

    NEXT YEAR, SOMETIME .......................On my way to the Bank ........................
    Perhaps The Strongest "I Told You So"

    Sentiment: Strong Buy

  • Reply to

    What A MannKind Investor Needs To Know

    by pfw2141 Jul 2, 2015 11:24 AM
    pfw2141 pfw2141 Jul 2, 2015 11:30 AM Flag

    Any investor currently holding a position in the stock or planning to establish a position before the potential-blockbuster gets going must be open to more volatility in the stock. The price per share does not always behave the way news or progress may suggest. I have seen shorts beat the hell out of the stock on several occasions over the three year timeframe I have closely followed the biotech. MannKind has been the 5th most shorted stock on the NYSE. Currently, 120 million shares are held short, which represents more than an 8% decrease since May, when 131 million shares were held short. With so many short positions being reduced, the volatility of the stock is unclear. These shorts were not all wrong and their positions likely profited, but short interest is decreasing because they realize it is becoming time to buy. Shorts believed sales would be slow, which is what investors were told to expect by Sanofi/MannKind with the announcement of a soft launch. These shorts also believe they can make a killing because of MannKind's debt position. Yet, MannKind has milestone payments coming up, and $150 million of MannKind's "debt" is a prepayment by its partner, Sanofi. Their accounts payable have decreased significantly this year and currently hold over $120 million in cash. I also find confidence in the fact that almost 40% of the stock is owned by insiders, with less than 1 million shares sold by insiders over the past six months. Positive catalysts have the potential to force shorts to run for the hills in what is known as a "short-squeeze," which would drive the share price muchhigher.

  • Summary

    Afrezza prescriptions have increased week over week despite analysis insisting on calling the planned soft launch a "failed launch".
    Afrezza is still not Exubera.
    The Technosphere platform is the closest thing to disruptive technology the diabetes market has ever seen.
    Afrezza has a healthy buzz across social media with overwhelmingly positive testimonials, which is yet another form of DTC awareness.
    Insurance coverage is the greatest hurdle for Sanofi and MannKind in the short run, but providers, such as Humana will make their decision on Afrezza coverage in the near term.

    Afrezza is just the first drug to arrive on MannKind's (NASDAQ:MNKD) Technosphere platform. Afrezza is not Exubera.
    In fact, patients have praised the new inhalable insulin therapy since its February launch. Afrezza delivers relief instantly, in fewer milligrams, and with a much smaller Dreamboat device. The Technosphere platform can be described as a disruptive technology that the diabetes market hasn't seen for a while. Honestly, I could go on, but those are the top three in my opinion

    Sentiment: Strong Buy

  • MannKind investors were disappointed when its marketing partner Sanofi revealed that Afrezza generated only $1.1 million sales in the first two months of launch. On the other hand, RBC Capital Markets analyst Adnan Butt and Jefferies analyst Shaunak Deepak have reiterated that Afrezza sales are picking up, albeit slowly. The two research firms have been keeping close tabs on the prescription numbers of MannKind's inhaled insulin treatment.

    Sentiment: Buy

  • Reply to

    The 6 Most Heavily Shorted Nasdaq Stocks in June

    by pfw2141 Jun 26, 2015 10:31 AM
    pfw2141 pfw2141 Jun 26, 2015 10:32 AM Flag

    post twice maybe ..............

  • The Product is great for some, and the Management are on the right track, our BIG PROBLEMS, manipulation and short. One of the 6 most shorted
    MannKind Corp.’s (NASDAQ: MNKD) short interest, at more than 120.42 million shares as of June 15, was down 8.2% from the previous period. Note that it was 47% of the total float, as well as the second highest short interest in at least a year. The days to cover dropped from more than 12 to about eight. In early June, it looked like MannKind had become a tug-o-war stock. Shares ended Wednesday at $5.85, in a 52-week range of $3.46 to $11.48. The stock saw a share price increase of more than 40% in early June, though it gave up much of that gain by the end of the two-week short-interest period.

    Sentiment: Buy

  • Product is great, but manipulation is terrible, nothing to do with Management team............

    MannKind Corp.’s (NASDAQ: MNKD) short interest, at more than 120.42 million shares as of June 15, was down 8.2% from the previous period. Note that it was 47% of the total float, as well as the second highest short interest in at least a year. The days to cover dropped from more than 12 to about eight. In early June, it looked like MannKind had become a tug-o-war stock. Shares ended Wednesday at $5.85, in a 52-week range of $3.46 to $11.48. The stock saw a share price increase of more than 40% in early June, though it gave up much of that gain by the end of the two-week short-interest period.

    Sentiment: Strong Buy

  • I am sure everyone already know this article , I bought few more K, just from the news ...... need more articles weekly.

    Boston drug company Keryx continues to shake off the haters
    Jun 24, 2015, 11:39am EDT
    Don Seiffert
    Boston Business Journal
    , the Baupost Group has increased its “long” shares to 22.4 million shares (22 percent of the company's total) as of June 15. In an interview a month ago, Jason Kolbert, an analyst at Maxim, told me that he’s confident Auryxia will become widely used, because it’s simply a better drug than current phosphate binders. The question, he said, is when.

    Kolbert said at the time he was expecting Keryx to report second quarter Auryxia revenue of $4 million, and third quarter revenue of $8 million. But, he said, if Keryx is able to significantly beat those estimates, it would force the short investors to give up, and clear the way for a fast increase in Keryx’s stock price.

    Sentiment: Strong Buy

  • Reply to

    For the NEWCOMER , IF ANY!

    by pfw2141 Jun 23, 2015 12:12 PM
    pfw2141 pfw2141 Jun 23, 2015 12:55 PM Flag

    Few newcomers are Doctor and Patients, they invest to be in touch with what going on with the progress of MNKD products.
    Few good Friends of mine in Paris, have bought few K because they are curious about the Dreamboat, who could be used for their asthma, word of mouth is a strong way of communication.

    Sentiment: Buy

  • CHICAGO, June 16, 2015 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MNKD, LEN, AET, YELP and ZU. To see what our analysts have discovered about a particular stock, read the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. (Note: You may have to copy this link into your browser then press the [ENTER] key.)

    Shares Outstanding 409.58M
    Float 256.8M

    Shares Short 131.16M
    Short Ratio 12.4
    Short % of Float 51.07% This is where is our problem No 1
    As of 5/29/2015

    MannKind Corporation (MannKind) is a biopharmaceutical company focused on the discovery and development of therapeutic products for diseases, such as diabetes. The Company's product candidate is AFREZZA, inhaled insulin used to control high blood sugar in adults with type one and type two diabetes and also to improve glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a small and portable inhaler. AFREZZA utilizes its Technosphere formulation technology. The Company's Technosphere powders are -based on the Company's fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format. The Company manufactures AFREZZA in its Danbury, Connecticut facility.

    Sentiment: Buy

  • pfw2141 pfw2141 Jun 23, 2015 10:07 AM Flag

    What don't you call Mat and talk to him about your concern and let us know if is any good news coming up,ASAP
    nvestor Relations
    Matthew J. Pfeffer
    Corporate Vice President and Chief Financial Officer
    (661) 295-4784
    - See more at: http://www.mannkindcorp.com/about-us-contact-us.htm#sthash.wiDi9iJ2.dpuf

  • Reply to

    From the Novo Nordisk A/S Message Board

    by pfw2141 Jun 19, 2015 12:10 PM
    pfw2141 pfw2141 Jun 19, 2015 1:00 PM Flag

    yes your statement is correct, few, but only few are posting on NVO, maybe they own some NVO stock, however if that work, good for us

  • I was visiting the competition, and amaze of the popularity of MNKD,
    FROM THEIR BOARD.
    Afrezza new diabetic inhale will kill NVO stock pretty soon just sell and run as fast as you can before you lose it
    It's a pretty sure bet. If Goldman and Cramer are trying to knock it down (while Goldman accumulates millions of shares and probably Cramer too), it is a GREAT BET... buy MNKD--- new Technosphere applications every six months.

    Just Buy MNKD

    Afrezza works - better than advertised. Buy out MNKD. Chump change for yo

    Afrezza is the Advanced Delivery System for Insulin

    MNKD
    built a better mousetrap !!!

    and it's good for more than insulin only... will replace many injectables over the next few year

    AND MANY MANY MORE STATEMENT
    I am surprise that all our US and European Doctors are NOT very knowledgeable about Afrezza, when so many people talking about the product.!!

    Sentiment: Strong Buy

  • Reply to

    synthetic insulin vs human insulin in Germany

    by kimi_held Jun 14, 2015 2:33 AM
    pfw2141 pfw2141 Jun 18, 2015 10:07 AM Flag

    Good post, we should be back to $6.00 very soon

  • Reply to

    synthetic insulin vs human insulin in Germany

    by kimi_held Jun 14, 2015 2:33 AM
    pfw2141 pfw2141 Jun 17, 2015 10:03 AM Flag

    En France les Toubibs sent foutes, tout est gratuit, il suffit seulement de leur faire connaitre Afrezza! that All!
    Look like we having a meeting at the United Nations, we should invited the Chinese , they are the most affected with the diabetes because of 3 serving of rice every day.
    Deutschland über alles et vive La France!
    a little humor does not hurt!

    If I am correct, in Germany shorting any stock are VERBOTEN, I like that
    MNKN THIS MORNING
    Shares Outstanding 409.58M
    Float 256.8M

    Shares Short 131.16M
    Short Ratio 12.4
    Short % of Float 51.07%

    Sentiment: Strong Buy

  • Reply to

    A stock market crash could send MNKD to $20.

    by msch8864 Jun 15, 2015 9:39 AM
    pfw2141 pfw2141 Jun 15, 2015 10:32 AM Flag

    Dow falls 150 points into the red and MNKD IS UP, you may be on something ..............

    Sentiment: Strong Buy

  • Reply to

    DID WE REALLY NEED THE CFO TO SAY THIS??

    by izmatic01 Jun 15, 2015 8:26 AM
    pfw2141 pfw2141 Jun 15, 2015 8:57 AM Flag

    He will get some respect to be honest, and prior anything some trust, when the great news come up, the stock too.

    Sentiment: Strong Buy

  • pfw2141 pfw2141 Jun 9, 2015 12:21 PM Flag

    Good for you, have a glass of red wine, cabernet bien sur and enjoy your life again, don't forget to send a thank you note to our good Mr Mann.

    Sentiment: Strong Buy

  • Reply to

    Here's why Adam Fartstain is a lying gash:

    by warrenbluffed Jun 9, 2015 11:11 AM
    pfw2141 pfw2141 Jun 9, 2015 11:42 AM Flag

    Most of the people who sold today, was probably on"Margin" yesterday.............off the hook jmho
    we may closed o the green today
    I bought few more and I am not the only one!!

    Sentiment: Strong Buy

  • FINALLY, this Gentlemen should get a Nobel Price for his achievement FINALLY
    The whole world will learn about Mr Mann and our stock should go to the roof.
    BOSTON, June 9, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD), a leading biopharmaceutical company focused on patient experience, acknowledged today that Executive Chairman Alfred Mann was honored last night at a gala for his extensive work in the progression and advancement of diabetes technologies and advocacy.

    Held in conjunction with the 75th annual American Diabetes Association Scientific Sessions in Boston, the reception was co-hosted by Kelly L. Close, leading diabetes advocate and founder of the diaTribe Foundation, along with Dr. Steven Edelman, nationally recognized endocrinologist and founder of Take Control of Your Diabetes (TCOYD). In addition to last night's honors, Mr. Mann was also recently awarded the JDRF's Lifetime Achievement Award, one of the leading awards in diabetes internationally.

    Sentiment: Strong Buy

AEZS
0.272-0.003(-1.09%)Jul 2 4:00 PMEDT